Immatics N.V. Ordinary Shares (IMTX)
Stock · NASDAQ · Health Care
$9.45as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$9.74
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipel…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 704
- Website
- immatics.com/
Fundamentals
- 1-day range
- $9.32$9.88
- Market cap
- $1.21B
- P/E (trailing)
- —
- P/E (forward)
- -4.57
- EPS (trailing)
- $-1.71
- Dividend yield
- —
- Beta
- 1.35
- Avg. volume
- 485.5K
52-week range
$5.05$12.41
Next earnings: November 17, 2026 · EPS estimate $-0.50confirmed
Forecasts
6 analyst ratings
Buy 94%
Hold 6%
Sell 0%
1-year price forecast
High
$25
+164.6%
Median
$17
+79.9%
Low
$11.8
+24.9%
Immatics N.V. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- IMTXImmatics N.V. Ordinary Shares$9.45▲ 0.91%Market cap $1.21BP/E —$5.05$12.41
- INBXInhibrx Biosciences Inc. Common Stock$123.93▼ 0.00%Market cap $1.21BP/E —$26.19$155.29
- VORVor Biopharma Inc. Common Stock$22.66▼ 3.70%Market cap $1.16BP/E —$6.5$49.95
- GLUEMonte Rosa Therapeutics Inc. Common Stock$13.37▼ 6.63%Market cap $1.30BP/E —$4.6$25.77
- MGTXMeiraGTx Holdings plc Ordinary Shares$13.8▼ 2.40%Market cap $1.10BP/E 15.54$6.62$15.35
- SANASana Biotechnology Inc. Common Stock$3.93▼ 3.91%Market cap $884.97MP/E —$2.61$6.55
- SLDBSolid Biosciences Inc. Common Stock$9.78▼ 3.46%Market cap $789.57MP/E —$3.79$11.45
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMTX Immatics N.V. Ordinary Shares | $1.21B | — | $9.45 | ▲ 0.91% | $5.05$12.41 |
| INBX Inhibrx Biosciences Inc. Common Stock | $1.21B | — | $123.93 | ▼ 0.00% | $26.19$155.29 |
| VOR Vor Biopharma Inc. Common Stock | $1.16B | — | $22.66 | ▼ 3.70% | $6.5$49.95 |
| GLUE Monte Rosa Therapeutics Inc. Common Stock | $1.30B | — | $13.37 | ▼ 6.63% | $4.6$25.77 |
| MGTX MeiraGTx Holdings plc Ordinary Shares | $1.10B | 15.54 | $13.8 | ▼ 2.40% | $6.62$15.35 |
| SANA Sana Biotechnology Inc. Common Stock | $884.97M | — | $3.93 | ▼ 3.91% | $2.61$6.55 |
| SLDB Solid Biosciences Inc. Common Stock | $789.57M | — | $9.78 | ▼ 3.46% | $3.79$11.45 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal MelanomaSeekingAlpha · 8/25/2026
- Immatics Announces $150M Underwritten Offering Of Ordinary Shares And Pre-Funded Warrantsbenzinga · 8/25/2026
- Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On TuesdayBenzinga · 8/25/2026
- Immatics Announces $150M Underwritten Offering Of Ordinary Shares And Pre-Funded WarrantsBenzinga · 8/25/2026
- Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor UpdatesSeekingAlpha · 8/20/2026
- Immatics Q2 EPS $(0.53) Misses $(0.43) Estimate, Sales $10.630M Miss $14.590M EstimateBenzinga · 8/18/2026
Insider Activity
Insider Actions →Acquired
1.06M
Disposed
0
- PERCEPTIVE ADVISORS LLC · August 26, 2026 · Buy863.1K @ $8.69
- Carter Paul Rutherford · June 16, 2026 · Grant48.0K
- Mason Heather L · June 16, 2026 · Grant48.0K
- PERCEPTIVE ADVISORS LLC · June 16, 2026 · Grant48.0K
- ATIEH MICHAEL G · June 16, 2026 · Grant48.0K
See the full, filterable feed with live charts on the MarketWall dashboard.